JP2025510942A5 - - Google Patents

Info

Publication number
JP2025510942A5
JP2025510942A5 JP2024557455A JP2024557455A JP2025510942A5 JP 2025510942 A5 JP2025510942 A5 JP 2025510942A5 JP 2024557455 A JP2024557455 A JP 2024557455A JP 2024557455 A JP2024557455 A JP 2024557455A JP 2025510942 A5 JP2025510942 A5 JP 2025510942A5
Authority
JP
Japan
Prior art keywords
disorder
indole
amine
pharmaceutical composition
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510942A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/058107 external-priority patent/WO2023186963A1/en
Publication of JP2025510942A publication Critical patent/JP2025510942A/ja
Publication of JP2025510942A5 publication Critical patent/JP2025510942A5/ja
Pending legal-status Critical Current

Links

JP2024557455A 2022-03-31 2023-03-29 亜酸化窒素及び5-ht2a受容体作動薬の組み合わせ Pending JP2025510942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362258P 2022-03-31 2022-03-31
US63/362,258 2022-03-31
PCT/EP2023/058107 WO2023186963A1 (en) 2022-03-31 2023-03-29 Combination of nitrous oxide and 5-ht2a receptor agonists

Publications (2)

Publication Number Publication Date
JP2025510942A JP2025510942A (ja) 2025-04-15
JP2025510942A5 true JP2025510942A5 (https=) 2026-04-06

Family

ID=86007250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557455A Pending JP2025510942A (ja) 2022-03-31 2023-03-29 亜酸化窒素及び5-ht2a受容体作動薬の組み合わせ

Country Status (5)

Country Link
EP (1) EP4499087A1 (https=)
JP (1) JP2025510942A (https=)
AU (1) AU2023242469A1 (https=)
CA (1) CA3247035A1 (https=)
WO (1) WO2023186963A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
EP4704806A1 (en) * 2023-05-05 2026-03-11 Cybin IRL Limited Injectable pharmaceutical formulations
CN121752545A (zh) * 2023-11-06 2026-03-27 宜昌人福药业有限责任公司 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途
WO2025099725A1 (en) * 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
DE4023108C1 (https=) 1990-07-20 1992-02-13 Ems Gmbh, 8520 Moehrendorf, De
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
ID28302A (id) 1999-01-14 2001-05-10 Teijin Ltd Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
CN1736502A (zh) 1999-03-03 2006-02-22 奥普蒂诺斯公司 鼻传送装置
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
WO2003026559A2 (en) 2001-09-28 2003-04-03 Kurve Technology, Inc Nasal nebulizer
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
US8826905B2 (en) 2007-06-01 2014-09-09 Ramses Nashed Respiratory face mask and breathing circuit assembly
US20100192947A1 (en) 2009-02-04 2010-08-05 Jeff Mandel Anesthetic delivery system and methods of use
CA2763021C (en) 2010-02-22 2013-03-05 Class 1 Inc. Apparatus, systems and methods for collecting and reclaiming anaesthetic agents and for removing nitrous oxide from exhaust gases
EP2589403B1 (en) 2011-05-31 2016-02-03 Ishikita, Naoyuki Anesthetic inhalation-assisting device
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний

Similar Documents

Publication Publication Date Title
JP2025510942A5 (https=)
JP2024533291A5 (https=)
Zhang et al. Research advances in the clinical application of esketamine
JP2023544724A5 (https=)
JP2013544850A5 (https=)
CN106562952B (zh) 氯胺酮在治疗重性抑郁障碍中的应用
JP2013537887A5 (https=)
JP2005539068A5 (https=)
AR076621A1 (es) Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador
JP2010532761A5 (https=)
JP2024522065A5 (https=)
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
KR20070083826A (ko) 우울증을 위한 부가 요법
Johnston et al. Esketamine in depression: putative biomarkers from clinical research
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
CA2588042A1 (en) Compositions and methods for pulmonary conditions
JP2012518019A5 (https=)
US20180177744A1 (en) Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
EP2696871B1 (en) Aclidinium for use in improving the quality of sleep in respiratory patients.
KR20060032598A (ko) 세로토닌 재흡수 억제제 및 아고멜라틴의 조합
JP2020506930A (ja) ベタヒスチンを含む鼻腔内組成物
JP2007505156A (ja) 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ
JP2011516604A (ja) 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の(1s,2r)鏡像異性体の使用
JP6346618B2 (ja) アクリジニウムの新規用途
Saxena et al. Comparison of nebulized ropivacaine (0.75%) with nebulized dexmedetomidine on the hemodynamic response on intubation in patients undergoing surgery under general anesthesia: A comparative randomized double-blind placebo-controlled study